Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $40.43 million for the quarter.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). The business had revenue of $41.83 million for the quarter, compared to analysts’ expectations of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Trading Up 0.6 %

Shares of Rhythm Pharmaceuticals stock opened at $64.41 on Tuesday. The firm has a market capitalization of $4.10 billion, a P/E ratio of -14.88 and a beta of 2.36. The business’s fifty day simple moving average is $56.09 and its 200 day simple moving average is $56.67. Rhythm Pharmaceuticals has a 12 month low of $35.17 and a 12 month high of $68.58.

Analyst Ratings Changes

RYTM has been the topic of a number of research analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Canaccord Genuity Group increased their target price on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. Wells Fargo & Company raised their price target on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an “overweight” rating in a research note on Monday, April 7th. Bank of America upgraded Rhythm Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $63.00 price objective on the stock in a research note on Monday, April 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price (up from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat, Rhythm Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $74.92.

Insiders Place Their Bets

In related news, EVP Yann Mazabraud sold 6,745 shares of the business’s stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $65.08, for a total transaction of $438,964.60. Following the sale, the executive vice president now directly owns 37,655 shares in the company, valued at approximately $2,450,587.40. The trade was a 15.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Christopher Paul German sold 635 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the transaction, the chief accounting officer now owns 2,070 shares of the company’s stock, valued at approximately $118,445.40. This represents a 23.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 151,733 shares of company stock worth $8,492,699 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.